Table 4

Adjusted HRs ; Adjustments were made for all parameters shown in the table

	Unadjusted HR		Adjusted HR: 6 (rituximab 12) months risk window approach			Adjusted HR: Ever exposed approach			Deaths	PYRS
	HR	95% CI	HR	95% CI	p Value	HR	95% CI	p Value	Deaths	PYRS
At baseline
Male	1.85	1.53 to 2.25	1.75	1.40 to 2.18	<0.0001	1.72	1.38 to 2.14	<0.0001	154	6718
Age per 5 years	1.66	1.57 to 1.75	1.49	1.40 to 1.59	<0.0001	1.50	1.41 to 1.60	<0.0001		31 378
Diabetes	3.43	2.77 to 4.26	1.84	1.46 to 2.33	<0.0001	1.85	1.46 to 2.33	<0.0001	108	2633
Chronic lung disease	3.31	2.63 to 4.17	1.68	1.31 to 2.17	0.0003	1.71	1.32 to 2.20	0.0002	89	2125
Chronic renal disease	4.90	3.71 to 6.47	1.94	1.43 to 2.63	0.0001	1.92	1.41 to 2.61	0.0002	57	926
Prior malignancy	3.15	2.27 to 4.37	1.26	0.88 to 1.80	0.20	1.27	0.89 to 1.81	0.18	39	927
Osteoporosis	2.86	2.38 to 3.43	1.43	1.16 to 1.76	0.0015	1.41	1.15 to 1.73	0.0020	199	6718
Coronary heart disease	4.94	4.00 to 6.10	1.43	1.12 to 1.83	0.006	1.46	1.14 to 1.86	0.0036	115	2017
Smoker	0.82	0.62 to 1.07	1.37	1.02 to 1.85	0.038	1.36	1.01 to 1.83	0.042	86	6936
At follow-up
DAS28* <3.2	Ref.		Ref.			Ref.			42	6730
DAS28* 3.2–4.1	1.81	1.21 to 2.71	1.15	0.76 to 1.74	0.49	1.11	0.74 to 1.68	0.59	99	8875
DAS28* >4.1 to 5.1	2.29	1.57 to 3.33	1.17	0.78 to 1.75	0.43	1.08	0.72 to 1.61	0.70	130	8773
DAS28>5.1	4.86	3.35 to 7.04	1.75	1.14 to 2.68	0.013	1.54	1.00 to 2.38	0.0499	192	6999
Prednisone most recent 12 months: 0 mg/d	Ref.		Ref.			Ref.			88	9036
1–5 mg/d	1.33	1.00 to 1.76	1.05	0.80 to 1.38	0.71	1.04	0.79 to 1.37	0.77	177	13 615
>5–10 mg/d	2.22	1.65 to 2.98	1.46	1.09 to 1.95	0.013	1.41	1.06 to 1.89	0.021	140	7086
>10–15 mg/d	3.95	2.61 to 5.98	2.00	1.29 to 3.11	0.0033	2.01	1.30 to 3.11	0.0030	37	1170
>15 mg/d	6.68	4.06 to 11.0	3.59	2.11 to 6.13	<0.0001	3.43	2.01 to 5.86	<0.0001	21	448
FFbH* in % of full function per 10% improvement	0.76	0.73 to 0.79	0.88	0.84 to 0.93	<0.0001	0.89	0.85 to 0.93	<0.0001		31 378
Methotrexate	Ref.		Ref.			Ref.			96†/78‡	7012†/6469‡
Other synth. DMARDs	2.53	1.95 to 3.28	1.14	0.86 to 1.51	0.36	0.98	0.60 to 1.59	0.92	126†/31‡	3513†/1581‡
TNFα inhibitors	0.77	0.61 to 0.98	0.64	0.50 to 0.81	0.0007	NA			182†	16 843†
Rituximab	1.01	0.70 to 1.46	0.57	0.39 to 0.84	0.0062	NA			36†	2599†
TNFα inhibitors or rituximab	NA		NA			0.77	0.60 to 0.97	0.0312	330‡	22 370‡
Other biologics	1.02	0.68 to 1.52	0.64	0.42 to 0.99	0.043	0.91	0.66 to 1.25	0.54	25†/51‡	1654†/2806‡
DAS28>4.1 for > 6 (12) months after discon- tinuation of a biologic without start of a new one	NA		NA			2.08	1.59 to 2.72	<0.0001	86‡	1812‡

*Average of single DAS28 or FFbH scores between baseline and last time point prior to the event, FFbH: Function questionnaire (see Methods) (range 0–100%).
†Risk window approach.
‡Ever exposed approach.
DMARD, disease modifying antirheumatic drugs; PYRS: patient years; Ref., referent.